DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: The national cooperative study by the Japan society for hypothalamic and pituitary tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 3, 2013, Pages 1130-1136

  Hirohata, Toshio ^a   Asano, Kenichiro ^c   Ogawa, Yoshikazu ^d   Takano, Shingo ^e   Amano, Kosaku ^f   Isozaki, Osamu ^f   Iwai, Yoshiyasu ^g   Sakata, Kiyohiko ^h   Fukuhara, Noriaki ⁱ   Nishioka, Hiroshi ⁱ   Yamada, Shozo ⁱ   Fujio, Shingo ^j   Arita, Kazunori ^j   Takano, Koji ^a   Tominaga, Atsushi ^k   Hizuka, Naomi ^o   Ikeda, Hidetoshi ^l   Osamura, R Yoshiyuki ^m   Tahara, Shigeyuki ^e   Ishii, Yudo ⁿ   Kawamata, Takakazu ^f   Shimatsu, Akira ^p   Teramoto, Akira ^k   Matsuno, Akira ^b   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d Konan Hospital   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g OSAKA CITY GENERAL HOSPITAL   (Japan)

^h KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ TORANOMON HOSPITAL   (Japan)

^j KAGOSHIMA UNIVERSITY   (Japan)

^k HIROSHIMA UNIVERSITY   (Japan)

^l Southern Tohoku General Hospital   (Japan)

^m International University of Health and Welfare Mita Hospital   (Japan)

ⁿ NIPPON MEDICAL SCHOOL   (Japan)

^o Tokyo Women s Medical University   (Japan)

^p NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOHYPOPHYSIS HORMONE; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MSH6; PROTEIN P53; TEMOZOLOMIDE;

ACTH SECRETING ADENOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS CARCINOMA; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; JAPAN; MALE; NONFUNCTIONING PITUITARY ADENOMA; NULL CELL ADENOMA; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADENOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DATA COLLECTION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; KI-67 ANTIGEN; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84874825652     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2924     Document Type: Article

References (34)

1. DeLellis RA, Lloyd R, Heitz PU, eds. 2004 WHO Classification of Tumors, Pathology and Genetics: Tumors of Endocrine Organs. Lyon, France: IARC Press.
2. Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38:9-107.
3. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005;90:3089-3099.
4. Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV. Pathology of invasive pituitary tumors with special references of functional classification. J Neurosurg. 1986;65:733-744. (Pubitemid 17187407)
5. Hermisson M, Klumpp A, Wick W, et al. O6-Methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 2006;96(3):766-776.
6. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20(5): 1375-1382. (Pubitemid 34177445)
7. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13:2986-2991. (Pubitemid 46849574)
8. Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95(10): 4592-4599.
9. Syro LV, Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide. Cancer. 2011;117:454-462.
10. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
11. Hunter C, Smith R, Cahill DP, et al. Ahypermutation phenotype and somatic MSH6 mutations in human malignant gliomas after alkylataorchemotherapy. Cancer Res. 2006;66(8):3987-3991.
12. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatmen. Clin Cancer Res. 2007;13(7):2038-2045. (Pubitemid 46649870)
13. Losa M, Mazza E, Terreni MR, et al. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol. 2010;163: 843-851.
14. Bush ZM, Longtine JA, Cunningham T, et al. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 2010;95: E280-E290.
15. Park DK, Ryan CW, Dolan ME, Vogelzang NJ, Stadler WM. A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol. 2002;50(2):160-162.
16. Trudeau ME, Crump M, Charpentier D, et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Ann Oncol. 2006;17(6):952-956. (Pubitemid 43778985)
17. Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab. 1998;83:4233-4238. (Pubitemid 29100114)
18. Pernicone PJ, Scheithauer BW, Sebo TJ, et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer. 1997;79:804-812. (Pubitemid 27076347)
19. Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF Jr, Lloyd RV. Pituitary carcinoma: a clinicopathological review. Neurosurgery. 2005;56:1066-1074. (Pubitemid 40628116)
20. Kovacs K, Scheithauer BW, Lombardero M, et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 2008;115:261-262.
21. McCormack AI, McDonald KL, Gill AJ, et al. Low O6-methylguanine-DNA- methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf). 2009;71:226-233.
22. Salehi F, Scheithauer BW, Kros JM, et al. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J Neurooncol. 2011;104:647-657.
23. Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harbor Perspect Biol. 2010;2: a001016.
24. Bocangel D, Sengupta S, Mitra S, Bhakat KK. p53-mediated downregulation of the human DNA repair geneO6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res. 2009;29(10):3741- 3750.
25. Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, et al. p53 gene mutations in pituitary carcinomas. Endocr Pathol. 2007;18:217-222.
26. Martin SA, Lord CJ, Ashworth. A therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res. 2010;16(21):5107-5113.
27. Wang JY, Edelmann W. Mismatch repair proteins as sensors of alkylation DNA damage. Cancer Cell. 2006;9:417-418. (Pubitemid 43842122)
28. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009;15:4622-4629.
29. Murakami M, Mizutani A, Asano S, et al. Amechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery. 2011;68:E1761-E1767.
30. Ikeda H, Abe T, Watanabe K. Usefulness of composite methioninepositron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. J Neurosurg. 2010;112:750-755.
31. Moshkin O, Syro LV, Scheithauer BW, et al. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy. Hormones. 2011;10(2):162-167.
32. Jouanneau E, Wierinckx A, Ducray F, et al. New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary. 2012;15(1):37-43.
33. Bode H, Seiz M, Lammert A, et al. SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTHs ecretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes. 2010;118:760-763.
34. Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL. Temozolomide (Temodar) and capecitabine (Xeloda) treatment of an aggressive corticotroph pituitary tumor. Pituitary. 2011;14(4): 418-424.